Cellectis (CLLS) Capital Leases (2021 - 2022)
Cellectis (CLLS) posted quarterly Capital Leases of $89000.0 for Q1 2022, down 99.49% quarter-over-quarter from $17.5 million in Q4 2021.
Cellectis (CLLS) Capital Leases (2021 - 2022) Analysis & Trends
Cellectis' Capital Leases history runs 2 years deep, the most recent figure standing at $89000.0 for Q1 2022.
- In Q1 2022, Capital Leases changed N/A year-over-year to $89000.0; the TTM figure through Mar 2022 stood at $89000.0 (changed N/A YoY), while the FY2021 annual figure was $17.5 million, changed N/A from the prior year.
- Capital Leases for Q1 2022 stood at $89000.0, down from $17.5 million in the prior quarter.
- The five-year high for Capital Leases was $17.5 million in Q4 2021, with the low at $89000.0 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 89,000.00 |
| Dec 31, 2021 | 17.51 Mn |